RefleXion Medical

By leveraging positron emission tomography (PET), the gold standard in cancer imaging and staging in a novel way, RefleXion’s patented technology* causes tumors to continuously signal their location during radiotherapy.

Launch date

2009

Employees

201-500 people

Market cap

Enterprise valuation

€500m (Public information from Nov 2023)

Hayward California (HQ)

https://reflexion.com/

https://twitter.com/reflexionmed https://www.linkedin.com/company/reflexion-medical

View job openings

Date	Investors	Amount	Round
-	TPG Exor Exor Ventures	N/A	-
Apr 2014	Sofinnova Partners Venrock Pfizer	$11.6m	Series A
Apr 2016	Sofinnova Partners Venrock Pfizer KCK Johnson & Johnson Innovation	$46.0m	Series B
Apr 2018	Sofinnova Partners Venrock Johnson & Johnson Pfizer KCK The Rise Fund (TPG) GT Healthcare T. Rowe Price	$100m	Series C
May 2019	Oxford Finance	$60.0m	Debt
Apr 2020*	Sofinnova Partners Venrock KCK Johnson & Johnson Innovation The Rise Fund (TPG) PSP Investments Pfizer Ventures T. Rowe Price	$110m Valuation: $485m	Series D
Mar 2021	Ally Bridge Group	$40.0m Valuation: $550m	Series D
Mar 2022*	Venrock KCK Johnson & Johnson Innovation The Rise Fund (TPG) Hillenbrand Ally Bridge Group PSP Investments Pfizer Ventures T. Rowe Price Catalio Capital Management Sixty Degree Capital Ascension Ventures	$80.0m Valuation: $550m	Late VC
Jul 2022*	Oxford Finance	$125m	Debt
Nov 2023*	The Rise Fund (TPG)	$105m Valuation: $550m	Late VC
Total Funding		€448m

Tech stackLearn more about the technologies and tools that this company uses.

RefleXion Medical

RefleXion Medical

Related Content

Recent News about RefleXion Medical

Tech stack